Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the sequencing of BTK inhibitors in chronic lymphocytic leukemia (CLL). The currently approved BTK inhibitors are all covalent inhibitors, meaning sequencing is not advisable if a patient progresses. Dr Brown highlights the potential of non-covalent BTK inhibitors, such as pirtobrutinib, for treatment following patient progression on covalent BTK inhibitors. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть